Alglucosidase alfa

Drug Profile

Alglucosidase alfa

Alternative Names: Alglucosidase alpha; human acid alpha-glucosidase; Lumizyme; Myozyme; Pompase; recombinant human acid alpha-glucosidase; rhGAA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Alpha-glucosidases; Peptides
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glycogen storage disease type II

Most Recent Events

  • 25 Jul 2016 Biomarkers information updated
  • 01 Aug 2014 US FDA approves sBLA for alglucosidase alfa (Lumizyme®) for patients of any age or phenotype with Glycogen storage disease type II in USA
  • 02 Sep 2013 Genzyme initiates enrolment in the phase IV PAPAYA trial for Pompe's disease in US, Germany, India, Russia and Ukraine (NCT01410890)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top